Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Randall Jacobs

Gastroenterology Fort Myers, FL Medical Doctor

NPI 1093798316 CMS profile 186111

9800 S Healthpark Dr Ste 110, Fort Myers, FL 33908

Open in the dashboard

General payments

$9,866

448 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Randall Jacobs of Fort Myers, FL is reported in the CMS Open Payments database as having received $9,866 across 448 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $596 11
2024 General $1,159 27
2023 General $2,328 98
2022 General $2,129 103
2021 General $1,309 67
2020 General $569 23
2019 General $1,776 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Randall Jacobs
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Randall Jacobs were reported at $596. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Randall Jacobs Gastroenterology median Middle half National median
2019 $1,776 $417 $126–$1,100 $163
2020 $569 $224 $74–$624 $114
2021 $1,309 $352 $106–$1,054 $132
2022 $2,129 $448 $129–$1,270 $149
2023 $2,328 $533 $150–$1,390 $160
2024 $1,159 $605 $160–$1,606 $164
2025 $596 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,221 82 payments
  2. Janssen Biotech, Inc. $1,171 55 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $932 71 payments
  4. Celgene Corporation $745 52 payments
  5. Genzyme Corporation $500 17 payments
  6. Gilead Sciences, Inc. $466 13 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $453 26 payments
  8. Regeneron Healthcare Solutions, Inc. $382 9 payments
  9. Ironwood Pharmaceuticals, Inc $315 16 payments
  10. Phathom Pharmaceuticals, Inc. $278 6 payments
  11. Other $2,401 101 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,831 447 payments
  2. Gift $34 1 payment
Products named General payments · program years 2019–2025
  1. STELARA $1,169 56 payments
  2. ZEPOSIA $959 52 payments
  3. SKYRIZI $713 19 payments
  4. RINVOQ $580 22 payments
  5. DUPIXENT Immunology $500 17 payments
  6. DUPIXENT Inflammation And Immunology $382 9 payments
  7. HUMIRA $361 22 payments
  8. TREMFYA $361 4 payments
  9. XIFAXAN $359 19 payments
  10. Entyvio $358 28 payments
  11. Other $5,303 271 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

593

Median for Gastroenterology: 569

Drug cost

$50,476

Median for Gastroenterology: $104,976

Branded share of claims

42.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 49 $40,838
Pantoprazole Sodium Generic 209 $2,743
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 171 $2,354
Mesalamine Generic 11 $1,667
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 12 $800
Omeprazole Generic 66 $733
Rabeprazole Sodium Generic 12 $379
Dicyclomine Hcl Generic 14 $366
Famotidine Generic 29 $335
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 20 $262

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$66,899

Medicare's payments for the services billed

Medicare patients

271

Average age 76

Services billed

627

142 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 41%
Diabetes 30%
Chronic kidney disease 23%
Atrial fibrillation 20%
Cancer 20%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $278
$278 — —
RINVOQ
  • AbbVie, Inc. $150
$150 — —
SKYRIZI
  • AbbVie, Inc. $135
$135 — —
ZEPOSIA
  • E.R. Squibb & Sons, L.L.C. $125
$125 — —
STELARA
  • Janssen Biotech, Inc. $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

448 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record